Roger S. Newton

7.8k total citations · 2 hit papers
92 papers, 6.5k citations indexed

About

Roger S. Newton is a scholar working on Surgery, Molecular Biology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Roger S. Newton has authored 92 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Surgery, 40 papers in Molecular Biology and 16 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Roger S. Newton's work include Lipoproteins and Cardiovascular Health (38 papers), Cholesterol and Lipid Metabolism (25 papers) and Peroxisome Proliferator-Activated Receptors (19 papers). Roger S. Newton is often cited by papers focused on Lipoproteins and Cardiovascular Health (38 papers), Cholesterol and Lipid Metabolism (25 papers) and Peroxisome Proliferator-Activated Receptors (19 papers). Roger S. Newton collaborates with scholars based in United States, Russia and Canada. Roger S. Newton's co-authors include Michael Aviram, Mira Rosenblat, Charles L. Bisgaier, Brian R. Krause, C L Bisgaier, Bert N. La Du, S.L. Primo-Parmo, Stephen L. Pinkosky, Scott S. Billecke and Robert C. Sorenson and has published in prestigious journals such as Journal of Biological Chemistry, Circulation and Journal of Clinical Investigation.

In The Last Decade

Roger S. Newton

90 papers receiving 6.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.

1998 984 citations Michael Aviram, C L Bisgaier et al. profile →
Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants

1999 523 citations Michael Aviram, Charles L. Bisgaier et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roger S. Newton United States	43	2.9k	1.8k	1.8k	1.5k	895	92	6.5k
Charles L. Bisgaier United States	29	1.4k 0.5×	1.4k 0.8×	1.3k 0.8×	932 0.6×	473 0.5×	57	4.4k
Tony Hayek Israel	47	2.8k 1.0×	2.4k 1.3×	847 0.5×	2.3k 1.6×	787 0.9×	111	9.8k
Daniel Steinberg United States	25	2.7k 0.9×	2.3k 1.2×	695 0.4×	1.2k 0.8×	611 0.7×	58	10.7k
John C. Khoo United States	25	2.1k 0.7×	2.0k 1.1×	530 0.3×	1.0k 0.7×	507 0.6×	48	8.1k
Ganesamoorthy Subbanagounder United States	27	1.3k 0.4×	1.8k 1.0×	827 0.5×	714 0.5×	324 0.4×	29	5.2k
Arie van Tol Netherlands	51	3.8k 1.3×	2.0k 1.1×	709 0.4×	4.1k 2.8×	1.4k 1.5×	201	8.3k
Günther Jürgens Austria	37	1.9k 0.7×	1.7k 0.9×	553 0.3×	764 0.5×	536 0.6×	105	7.5k
Sharon Arrol United Kingdom	29	996 0.3×	550 0.3×	2.9k 1.6×	1.0k 0.7×	251 0.3×	43	4.7k
Bianca Fuhrman Israel	40	717 0.3×	1.2k 0.6×	1.1k 0.6×	651 0.4×	276 0.3×	87	6.4k
Franklin H. Epstein United States	6	1.4k 0.5×	1.2k 0.6×	452 0.3×	676 0.5×	287 0.3×	7	6.1k

Countries citing papers authored by Roger S. Newton

Since Specialization

Citations

This map shows the geographic impact of Roger S. Newton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger S. Newton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger S. Newton more than expected).

Fields of papers citing papers by Roger S. Newton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger S. Newton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger S. Newton. The network helps show where Roger S. Newton may publish in the future.

Co-authorship network of co-authors of Roger S. Newton

This figure shows the co-authorship network connecting the top 25 collaborators of Roger S. Newton. A scholar is included among the top collaborators of Roger S. Newton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger S. Newton. Roger S. Newton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thompson, Paul D., Diane MacDougall, Roger S. Newton, et al.. (2016). Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. Journal of clinical lipidology. 10(3). 556–567. 118 indexed citations

Pinkosky, Stephen L., et al.. (2015). Abstract 17608: Identification of a Tissue-specific Very Long-chain Acyl-CoA Synthetase Involved in the Inhibition of ATP-Citrate Lyase (ACL) by ETC-1002: A Novel Mechanism for Cholesterol Biosynthesis Inhibition in the Liver. Circulation. 132(suppl_3). 1 indexed citations

Thompson, Paul M., John Rubino, Matthew Janik, et al.. (2015). Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. Journal of clinical lipidology. 9(3). 295–304. 121 indexed citations

Gutiérrez, María J., Diane MacDougall, Jeffrey C. Hanselman, et al.. (2014). Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus. Arteriosclerosis Thrombosis and Vascular Biology. 34(3). 676–683. 135 indexed citations

Srivastava, Rai Ajit K., Stephen L. Pinkosky, С. И. Филиппов, et al.. (2012). AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. Journal of Lipid Research. 53(12). 2490–2514. 240 indexed citations

Burnett, John R., Lisa J. Wilcox, Dawn E. Telford, et al.. (1999). The Magnitude of Decrease in Hepatic Very Low Density Lipoprotein Apolipoprotein B Secretion Is Determined by the Extent of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition in Miniature Pigs1. Endocrinology. 140(11). 5293–5302. 46 indexed citations

Bisgaier, Charles L., Arnold D. Essenburg, Bruce J. Auerbach, et al.. (1998). A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. Journal of Lipid Research. 39(1). 17–30. 53 indexed citations

Bisgaier, Charles L., et al.. (1998). Induction of PPARγ1 Expression in Human THP-1 Monocytic Leukemia Cells by 9-cis-Retinoic Acid Is Associated with Cellular Growth Suppression. Biochemical and Biophysical Research Communications. 251(3). 842–848. 25 indexed citations

Bisgaier, C L, Arnold D. Essenburg, Bruce J. Auerbach, et al.. (1997). Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors. Journal of Lipid Research. 38(12). 2502–2515. 66 indexed citations

10.

Wölle, Joachim, et al.. (1996). Selective Inhibition of Tumor Necrosis Factor–Induced Vascular Cell Adhesion Molecule-1 Gene Expression by a Novel Flavonoid. Arteriosclerosis Thrombosis and Vascular Biology. 16(12). 1501–1508. 50 indexed citations

11.

Spahr, Mark A., et al.. (1995). Gemfibrozil significantly lowers cynomolgus monkey plasma lipoprotein[a]-protein and liver apolipoprotein[a] mRNA levels.. Journal of Lipid Research. 36(6). 1294–1304. 27 indexed citations

12.

Krause, Brian R. & Roger S. Newton. (1995). Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis. 117(2). 237–244. 93 indexed citations

13.

Bocan, Thomas, Sandra Bak Mueller, Drago R. Sliskovic, et al.. (1994). Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation. Atherosclerosis. 111(1). 127–142. 70 indexed citations

14.

Sliskovic, Drago R., C. John Blankley, Brian R. Krause, et al.. (1992). Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5-disubstituted-pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones. Journal of Medicinal Chemistry. 35(11). 2095–2103. 16 indexed citations

15.

Saxena, Uday, et al.. (1992). Lipoprotein lipase-mediated lipolysis of very low density lipoproteins increases monocyte adhesion to aortic endothelial cells. Biochemical and Biophysical Research Communications. 189(3). 1653–1658. 30 indexed citations

16.

Roth, Bruce D., C. John Blankley, Alexander Chucholowski, et al.. (1991). Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran 2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus. Journal of Medicinal Chemistry. 34(1). 357–366. 151 indexed citations

17.

Sliskovic, Drago R., W. Howard Roark, Bruce D. Roth, et al.. (1991). Inhibitors of cholesterol biosynthesis. 4. trans-6-[2-(Substituted-quinolinyl)ethenyl/ethyl]tetrahydro-4-hydroxy-2H-pyran-2-ones, a novel series of HMG-CoA reductase inhibitors. Journal of Medicinal Chemistry. 34(1). 367–373. 44 indexed citations

18.

Sliskovic, Drago R., et al.. (1990). Inhibitors of cholesterol biosynthesis. 2. 1,3,5-Trisubstituted [2-(tetrahydro-4-hydroxy-2-oxopyran-6-yl)ethyl]pyrazoles. Journal of Medicinal Chemistry. 33(1). 31–38. 48 indexed citations

19.

Sircar, Ila, R. Steffen, Roger S. Newton, et al.. (1989). Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3(2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure. Journal of Medicinal Chemistry. 32(2). 342–350. 31 indexed citations

20.

Newton, Roger S., Robert E. Pitas, & R.G. Jensen. (1975). Effect of diet on fatty acids in the lipoprotein cholesteryl esters of type IIa and normal individuals. Lipids. 10(12). 858–862. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact